Biotech News

Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results

Twist Bioscience Corporation (TWST)Twist Bioscience CorporationEarnings

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 3, 2026-- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the third quarter fiscal 2026 ended June 30, 2026.

Related news

Twist Bioscience Corporation

Synthetic Biology Platform Twist Bioscience manufactures customizable synthetic DNA and related biological products at scale. Its platform is designed to improve the speed, throughput and precision of research and development workflows. Oligos and Genes Core products include oligonucleotides, genes and complex DNA constructs used by...

Recent company news

Stock data

Close
109.08 USD
Market cap
4.37B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States